Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 8/3/2018 |
| Start Date: | April 7, 2014 |
| End Date: | December 2024 |
| Contact: | Susan Staulcup |
| Email: | susan.staulcup@ucdenver.edu |
Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
New data suggests that the current treatment for pediatric adamantinomatous craniopharyngioma
(CPA) may not be as effective as it could be.
(CPA) may not be as effective as it could be.
Current treatment regimens for pediatric CPA are limited to surgery and radiation therapy.
This pilot study seeks to identify biologically rational therapeutics for the medical
treatment of adamantinomatous CPA by confirming the overexpression of specific molecules.
This pilot study seeks to identify biologically rational therapeutics for the medical
treatment of adamantinomatous CPA by confirming the overexpression of specific molecules.
Inclusion Criteria:
1. Patients between 0-21 years of age.
2. Patients with the diagnosis or clinical suspicion of craniopharyngioma in whom planned
clinical management will include tissue sampling.
Exclusion Criteria:
1. Patients in whom final pathology does not demonstrate adamantinomatous
craniopharyngioma
2. Patients in whom tissue specimen is not obtained/available
3. Patients over 21 years of age.
4. Patients who choose not to participate
We found this trial at
1
site
13123 E 16th Ave
Aurora, Colorado 80045
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Todd Hankinson, MD
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
Click here to add this to my saved trials
